Antibodies & Multispecifics

Monoclonal Antibody Partner

Monoclonal antibodies remain the foundation of modern biologic therapy and a natural starting point for Mabion’s innovative biologics positioning. The market remains large and resilient. Demand is driven by oncology, autoimmune diseases, chronic inflammation, respiratory disease, cardiovascular risk pathways and other conditions where selective target engagement can change disease biology. Our innovative solutions for antibody development streamline the workflow and increase productivity.

Mabion’s monoclonal antibody capabilities are grounded in a strong biosimilars development track record, including:

• MabionCD20, a rituximab biosimilar candidate with clinically confirmed efficacy and safety
• MabionEGFR, a cetuximab biosimilar candidate program

This experience supports the development of both biosimilar and innovative monoclonal antibodies, from cell line development and cGMP cell banking to GMP drug substance manufacturing readiness.

Antibodies Development and Manufacturing

Quality is at the center of Mabion’s monoclonal antibody services. Our team focus on stable, high-producing cell lines at the final CLD stage, QbD-based process development, and broad analytical control of structure, purity, potency, glycosylation, and other critical quality attributes. Offering two bioreactor technologies (impeller-driven stirred tank SUBs or orbital shaken SUBs) in various volumes tailored to pilot, clinical or commercial manufacturing needs.

Mabion’s approach is designed to support antibodies intended for demanding therapeutic areas where consistency, potency, and regulatory confidence are essential. By combining technological excellence with agility, compliance, and long-term partnership thinking, Mabion provides a reliable CDMO platform for monoclonal antibody programs that require scientific depth, supply security, and consistent product quality.

Mabion’s antibody services extends beyond conventional monoclonal antibodies to support next-generation antibody-based biologics, including bispecific, trispecific and multispecific formats. These advanced molecules are designed to engage multiple targets, epitopes or cell types, enabling more precise and differentiated mechanisms of action in oncology, immunology, inflammation and other complex therapeutic areas. Mabion’s capabilities may be applied to diverse antibody architectures, including:

• Fc fusion proteins
• Tandem Fab
• scFv-Fc
• DuoBody-type molecules
• Nanobody/VHH-type constructs
• Diabodies
• Other engineered antibody formats

Mabion provides a reliable CDMO environment for complex antibody formats from early development to scalable drug substance manufacturing.